Find disease awareness content and relevant supporting materials
Increased expression of miR-153 predicts poor prognosis for patients with prostate cancer.
Deregulation of miR-153 has recently been observed in several common human cancer, while miR-153 serves an oncogene or tumor suppressive role in different cancer types. Previously, miR-153 has been identified to be overexpressed in...
NICE recomends Tecentriq for use within the Cancer Drugs Fund as an option for adjuvant treatment after complete tumour resection in adults with stage 2 to 3a non-small-cell lung cancer
Atezolizumab is recommended for use within the Cancer Drugs Fund as an option for adjuvant treatment after complete tumour resection in adults with stage 2 to 3a non-small-cell lung cancer (NSCLC) whose: i. tumours have the programmed cell death ligand 1 (PD L1) biomarker expression on 50% or more of their tumour cells and ii. whose disease has not progressed after platinum-based adjuvant chemotherapy
Assess Efficacy & Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Positive NSCLC (SELECT-1)
The purpose of this study is to assess the efficacy of selumetinib in combination with docetaxel (75mg/m2) vs placebo in...
Driver genes as predictive indicators of brain metastasis in advanced NSCLC
Read the third publication digest on "Driver genes as predictive indicators of brain metastasis in advanced NSCLC" in this section of the Learning Zone.
NMPA(China) approves Tuoyi + chemotherapy to treat NSCLC without EGFR mutations or ALK fusions
The China National Medical Products Administration has approved the supplemental new drug application seeking the approval of toripalimab (Tuoyi) plus pemetrexed and platinum as a frontline treatment in patients with unresectable, locally advanced or metastatic, nonsquamous non–small cell lung cancer (NSCLC) who do not harbor EGFR mutations or ALK fusions
FDA approves Vegzelma biosimilar for Avastin in six types of cancer
Celltrion USA announced that the FDA has approved Vegzelma (bevacizumab-adcd), a biosimilar to Avastin (bevacizumab), for the treatment of six types of cancer: metastatic colorectal cancer; recurrent or metastatic non-squamous non-small cell lung cancer (nsNSCLC); recurrent glioblastoma; metastatic renal cell carcinoma; persistent, recurrent, or metastatic cervical cancer; and epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Osimertinib (AZD9291) decreases programmed death ligand-1 in EGFR-mutated non-small cell lung cancer cells.
Osimertinib (AZD9291) is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that has been approved for the treatment of EGFR-mutated non-small cell lung cancer (NSCLC).
Early plasma circulating tumor DNA (ctDNA) changes predict response to first-line pembrolizumab-based therapy in non-small cell lung cancer (NSCLC)
We sought to determine if changes in circulating tumor DNA (ctDNA) levels after initiation of first-line pembrolizumab±chemotherapy in NSCLC would enable early prediction of response prior to radiological assessment.